M06.9
Conditions
Interventions
Group 1: Patients with rheumatoid arthritis (RA), that are inculded in another trial in which one of their joints receives a synovial biopsy at the start of a new treatment will be included. For this
Sponsors
Medizinische Universität Wien, Universitätsklinik für Innere Medizin III, Klinische Abteilung für Rheumatologie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Ready and able to give informed consent - Starting a new DMARD therapy - Receiving a synovial biopsy in the course of another trial protocol (Vote number 2191/2019 or 1107/2024 from the ehtical committee of the Medical University of Vienna) - Evidence of active arthritis, prooven by one ore more swollen joint - Ready and able to undergo a FAPi PET/CT scan
Exclusion criteria
Exclusion criteria: - Patients with severe medical conditions (e. g. end stage renal disease) - Poor tolerance of venipuncture or failure to establish adequate venous access for the necessary blood sampling during the study period - Active infection - Pregnant or nursing women - Other serious acute or chronic medical or psychiatric conditions, or laboratory abnormalities, which, in the investigator’s judgement, would pose an excessive risk in connection with the trial or which, in the investigator’s judgement, would render the patient unsuitable for participation in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation between FAPi uptake (mean, maximal and peak standardised uptake value) and cell modules and molecular signatures from synovial biopsy at baseline. | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation between changes in FAPi and response to therapy (baseline to week 16). | — |
Countries
Austria
Contacts
Public ContactPeter Mandl
Medizinische Universität Wien, Universitätsklinik für Innere Medizin III, Klinische Abteilung für Rheumatologie
Outcome results
None listed